Literature DB >> 19559631

Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases.

Alexander U Lüthi1, Sean P Cullen, Edel A McNeela, Patrick J Duriez, Inna S Afonina, Clare Sheridan, Gabriela Brumatti, Rebecca C Taylor, Kristof Kersse, Peter Vandenabeele, Ed C Lavelle, Seamus J Martin.   

Abstract

Interleukin-33 (IL-33) is a member of the IL-1 family and is involved in polarization of T cells toward a T helper 2 (Th2) cell phenotype. IL-33 is thought to be activated via caspase-1-dependent proteolysis, similar to the proinflammatory cytokines IL-1 beta and IL-18, but this remains unproven. Here we showed that IL-33 was processed by caspases activated during apoptosis (caspase-3 and -7) but was not a physiological substrate for caspases associated with inflammation (caspase-1, -4, and -5). Furthermore, caspase-dependent processing of IL-33 was not required for ST2 receptor binding or ST2-dependent activation of the NF-kappaB transcription factor. Indeed, caspase-dependent proteolysis of IL-33 dramatically attenuated IL-33 bioactivity in vitro and in vivo. These data suggest that IL-33 does not require proteolysis for activation, but rather, that IL-33 bioactivity is diminished through caspase-dependent proteolysis within apoptotic cells. Thus, caspase-mediated proteolysis acts as a switch to dampen the proinflammatory properties of IL-33.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559631     DOI: 10.1016/j.immuni.2009.05.007

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  267 in total

1.  F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation.

Authors:  Jing Zhao; Jianxin Wei; Rachel K Mialki; Daniel F Mallampalli; Bill B Chen; Tiffany Coon; Chunbin Zou; Rama K Mallampalli; Yutong Zhao
Journal:  Nat Immunol       Date:  2012-06-03       Impact factor: 25.606

Review 2.  Research progress on interleukin-33 and its roles in the central nervous system.

Authors:  Ping Han; Wen-Li Mi; Yan-Qing Wang
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

Review 3.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

Review 4.  IL-33 family members and asthma - bridging innate and adaptive immune responses.

Authors:  Clare M Lloyd
Journal:  Curr Opin Immunol       Date:  2010-11-09       Impact factor: 7.486

5.  IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G.

Authors:  Emma Lefrançais; Stephane Roga; Violette Gautier; Anne Gonzalez-de-Peredo; Bernard Monsarrat; Jean-Philippe Girard; Corinne Cayrol
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

6.  A carbon nanotube toxicity paradigm driven by mast cells and the IL-₃₃/ST₂ axis.

Authors:  Pranita Katwa; Xiaojia Wang; Rakhee N Urankar; Ramakrishna Podila; Susana C Hilderbrand; Robert B Fick; Apparao M Rao; Pu Chun Ke; Christopher J Wingard; Jared M Brown
Journal:  Small       Date:  2012-07-06       Impact factor: 13.281

7.  Interleukin-33 in the human placenta.

Authors:  Vanessa Topping; Roberto Romero; Nandor Gabor Than; Adi L Tarca; Zhonghui Xu; Sun Young Kim; Bing Wang; Lami Yeo; Chong Jai Kim; Sonia S Hassan; Jung-Sun Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2012-11-23

8.  Serum amyloid A induces interleukin-33 expression through an IRF7-dependent pathway.

Authors:  Lei Sun; Ziyan Zhu; Ni Cheng; Qian Yan; Richard D Ye
Journal:  Eur J Immunol       Date:  2014-05-22       Impact factor: 5.532

9.  Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.

Authors:  Hayato Nakagawa; Nobumi Suzuki; Yoshihiro Hirata; Yohko Hikiba; Yoku Hayakawa; Hiroto Kinoshita; Sozaburo Ihara; Koji Uchino; Yuji Nishikawa; Hideaki Ijichi; Motoyuki Otsuka; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Norihiro Kokudo; Keisuke Tateishi; Kazuhiko Koike
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

10.  IL-33 activates tumor stroma to promote intestinal polyposis.

Authors:  Rebecca L Maywald; Stephanie K Doerner; Luca Pastorelli; Carlo De Salvo; Susan M Benton; Emily P Dawson; Denise G Lanza; Nathan A Berger; Sanford D Markowitz; Heinz-Josef Lenz; Joseph H Nadeau; Theresa T Pizarro; Jason D Heaney
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.